Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lexeo Therapeutics Inc LXEO

Healthcare Biotechnology
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a... see more

Recent & Breaking News (NDAQ:LXEO)

    Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

    GlobeNewswire 10 days ago

    Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

    GlobeNewswire October 30, 2024

    Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

    GlobeNewswire October 22, 2024

    Lexeo Therapeutics to Participate in Upcoming Investor Conferences

    GlobeNewswire September 5, 2024

    Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

    GlobeNewswire August 12, 2024

    Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

    GlobeNewswire July 15, 2024

    Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024

    GlobeNewswire July 11, 2024

    Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

    GlobeNewswire July 8, 2024

    Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

    GlobeNewswire May 9, 2024

    Lexeo Therapeutics to Participate in Upcoming Investor Conferences

    GlobeNewswire May 7, 2024

    Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

    GlobeNewswire April 22, 2024

    Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

    GlobeNewswire April 16, 2024

    Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

    GlobeNewswire March 13, 2024

    Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

    GlobeNewswire March 11, 2024

    Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

    GlobeNewswire March 11, 2024

    Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

    GlobeNewswire February 5, 2024

    Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    GlobeNewswire January 3, 2024

    Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

    GlobeNewswire December 18, 2023

    Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

    GlobeNewswire December 11, 2023